Genmab A/S
Genmab A/S (GNMSF) Stock Competitors & Peer Comparison
See (GNMSF) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GNMSF | $274.75 | +0.00% | 16.9B | 17.89 | $15.36 | N/A |
| NONOF | $36.68 | -0.19% | 162.7B | 10.40 | $3.52 | +4.66% |
| CSLLY | $23.96 | +0.00% | 92.7B | 15.54 | $1.54 | +3.06% |
| UCBJY | $146.67 | +1.40% | 55.8B | 31.77 | $4.61 | +0.54% |
| UCBJF | $292.69 | -4.02% | 55.7B | 31.68 | $9.24 | +0.52% |
| CMXHF | $95.07 | -6.53% | 46.1B | 15.41 | $6.17 | +3.06% |
| ARGNF | $708.72 | -13.03% | 43.9B | 36.23 | $19.56 | N/A |
| WXIBF | $4.60 | +0.00% | 19B | 32.86 | $0.14 | N/A |
| IVBXF | $10.77 | +0.00% | 18.5B | 107.70 | $0.10 | N/A |
| WXXWY | $8.60 | -2.38% | 17.8B | 31.22 | $0.28 | N/A |
Stock Comparison
GNMSF vs NONOF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, NONOF has a market cap of 162.7B. Regarding current trading prices, GNMSF is priced at $274.75, while NONOF trades at $36.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas NONOF's P/E ratio is 10.40. In terms of profitability, GNMSF's ROE is +0.14%, compared to NONOF's ROE of +0.61%. Regarding short-term risk, GNMSF is less volatile compared to NONOF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check NONOF's competition here
GNMSF vs CSLLY Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, CSLLY has a market cap of 92.7B. Regarding current trading prices, GNMSF is priced at $274.75, while CSLLY trades at $23.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas CSLLY's P/E ratio is 15.54. In terms of profitability, GNMSF's ROE is +0.14%, compared to CSLLY's ROE of +0.08%. Regarding short-term risk, GNMSF is more volatile compared to CSLLY. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check CSLLY's competition here
GNMSF vs UCBJY Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, UCBJY has a market cap of 55.8B. Regarding current trading prices, GNMSF is priced at $274.75, while UCBJY trades at $146.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas UCBJY's P/E ratio is 31.77. In terms of profitability, GNMSF's ROE is +0.14%, compared to UCBJY's ROE of +0.15%. Regarding short-term risk, GNMSF is more volatile compared to UCBJY. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check UCBJY's competition here
GNMSF vs UCBJF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, UCBJF has a market cap of 55.7B. Regarding current trading prices, GNMSF is priced at $274.75, while UCBJF trades at $292.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas UCBJF's P/E ratio is 31.68. In terms of profitability, GNMSF's ROE is +0.14%, compared to UCBJF's ROE of +0.15%. Regarding short-term risk, GNMSF is more volatile compared to UCBJF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check UCBJF's competition here
GNMSF vs CMXHF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, CMXHF has a market cap of 46.1B. Regarding current trading prices, GNMSF is priced at $274.75, while CMXHF trades at $95.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas CMXHF's P/E ratio is 15.41. In terms of profitability, GNMSF's ROE is +0.14%, compared to CMXHF's ROE of +0.08%. Regarding short-term risk, GNMSF is more volatile compared to CMXHF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check CMXHF's competition here
GNMSF vs ARGNF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, ARGNF has a market cap of 43.9B. Regarding current trading prices, GNMSF is priced at $274.75, while ARGNF trades at $708.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas ARGNF's P/E ratio is 36.23. In terms of profitability, GNMSF's ROE is +0.14%, compared to ARGNF's ROE of +0.34%. Regarding short-term risk, GNMSF is more volatile compared to ARGNF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check ARGNF's competition here
GNMSF vs WXIBF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, WXIBF has a market cap of 19B. Regarding current trading prices, GNMSF is priced at $274.75, while WXIBF trades at $4.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas WXIBF's P/E ratio is 32.86. In terms of profitability, GNMSF's ROE is +0.14%, compared to WXIBF's ROE of +0.10%. Regarding short-term risk, GNMSF is less volatile compared to WXIBF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check WXIBF's competition here
GNMSF vs IVBXF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, IVBXF has a market cap of 18.5B. Regarding current trading prices, GNMSF is priced at $274.75, while IVBXF trades at $10.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas IVBXF's P/E ratio is 107.70. In terms of profitability, GNMSF's ROE is +0.14%, compared to IVBXF's ROE of +0.08%. Regarding short-term risk, GNMSF is more volatile compared to IVBXF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check IVBXF's competition here
GNMSF vs WXXWY Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, WXXWY has a market cap of 17.8B. Regarding current trading prices, GNMSF is priced at $274.75, while WXXWY trades at $8.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas WXXWY's P/E ratio is 31.22. In terms of profitability, GNMSF's ROE is +0.14%, compared to WXXWY's ROE of +0.10%. Regarding short-term risk, GNMSF is more volatile compared to WXXWY. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check WXXWY's competition here
GNMSF vs SBMFF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, SBMFF has a market cap of 14.8B. Regarding current trading prices, GNMSF is priced at $274.75, while SBMFF trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas SBMFF's P/E ratio is 27.67. In terms of profitability, GNMSF's ROE is +0.14%, compared to SBMFF's ROE of +0.12%. Regarding short-term risk, GNMSF is more volatile compared to SBMFF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check SBMFF's competition here
GNMSF vs SBHMY Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, SBHMY has a market cap of 14.2B. Regarding current trading prices, GNMSF is priced at $274.75, while SBHMY trades at $15.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas SBHMY's P/E ratio is 25.63. In terms of profitability, GNMSF's ROE is +0.14%, compared to SBHMY's ROE of +0.12%. Regarding short-term risk, GNMSF is less volatile compared to SBHMY. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check SBHMY's competition here
GNMSF vs BRRGF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, BRRGF has a market cap of 9.5B. Regarding current trading prices, GNMSF is priced at $274.75, while BRRGF trades at $97.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas BRRGF's P/E ratio is -0.48. In terms of profitability, GNMSF's ROE is +0.14%, compared to BRRGF's ROE of -1.05%. Regarding short-term risk, GNMSF is less volatile compared to BRRGF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check BRRGF's competition here
GNMSF vs AAVXF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, AAVXF has a market cap of 9.1B. Regarding current trading prices, GNMSF is priced at $274.75, while AAVXF trades at $115.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas AAVXF's P/E ratio is -22.11. In terms of profitability, GNMSF's ROE is +0.14%, compared to AAVXF's ROE of +50.78%. Regarding short-term risk, GNMSF is more volatile compared to AAVXF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check AAVXF's competition here
GNMSF vs ODTC Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, ODTC has a market cap of 8B. Regarding current trading prices, GNMSF is priced at $274.75, while ODTC trades at $22,005.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas ODTC's P/E ratio is 1.07. In terms of profitability, GNMSF's ROE is +0.14%, compared to ODTC's ROE of +0.07%. Regarding short-term risk, GNMSF is more volatile compared to ODTC. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check ODTC's competition here
GNMSF vs AKBLF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, AKBLF has a market cap of 6.5B. Regarding current trading prices, GNMSF is priced at $274.75, while AKBLF trades at $32.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas AKBLF's P/E ratio is 38.77. In terms of profitability, GNMSF's ROE is +0.14%, compared to AKBLF's ROE of +0.20%. Regarding short-term risk, GNMSF is less volatile compared to AKBLF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check AKBLF's competition here
GNMSF vs TRSBF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, TRSBF has a market cap of 6.1B. Regarding current trading prices, GNMSF is priced at $274.75, while TRSBF trades at $2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas TRSBF's P/E ratio is 18.43. In terms of profitability, GNMSF's ROE is +0.14%, compared to TRSBF's ROE of +0.15%. Regarding short-term risk, GNMSF is less volatile compared to TRSBF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check TRSBF's competition here
GNMSF vs REGMF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, REGMF has a market cap of 5.6B. Regarding current trading prices, GNMSF is priced at $274.75, while REGMF trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas REGMF's P/E ratio is -32.26. In terms of profitability, GNMSF's ROE is +0.14%, compared to REGMF's ROE of +0.33%. Regarding short-term risk, GNMSF is more volatile compared to REGMF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check REGMF's competition here
GNMSF vs ABCZF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, ABCZF has a market cap of 5.1B. Regarding current trading prices, GNMSF is priced at $274.75, while ABCZF trades at $22.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas ABCZF's P/E ratio is 2225.00. In terms of profitability, GNMSF's ROE is +0.14%, compared to ABCZF's ROE of +0.29%. Regarding short-term risk, GNMSF is more volatile compared to ABCZF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check ABCZF's competition here
GNMSF vs LABFF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, LABFF has a market cap of 4.6B. Regarding current trading prices, GNMSF is priced at $274.75, while LABFF trades at $90.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas LABFF's P/E ratio is 28.95. In terms of profitability, GNMSF's ROE is +0.14%, compared to LABFF's ROE of +0.23%. Regarding short-term risk, GNMSF is more volatile compared to LABFF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check LABFF's competition here
GNMSF vs SHJBF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, SHJBF has a market cap of 4.1B. Regarding current trading prices, GNMSF is priced at $274.75, while SHJBF trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas SHJBF's P/E ratio is -25.00. In terms of profitability, GNMSF's ROE is +0.14%, compared to SHJBF's ROE of -0.14%. Regarding short-term risk, GNMSF is more volatile compared to SHJBF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check SHJBF's competition here
GNMSF vs CAMRF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, CAMRF has a market cap of 3.3B. Regarding current trading prices, GNMSF is priced at $274.75, while CAMRF trades at $55.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas CAMRF's P/E ratio is 41.98. In terms of profitability, GNMSF's ROE is +0.14%, compared to CAMRF's ROE of +0.19%. Regarding short-term risk, GNMSF is more volatile compared to CAMRF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check CAMRF's competition here
GNMSF vs GNNSF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, GNNSF has a market cap of 3.2B. Regarding current trading prices, GNMSF is priced at $274.75, while GNNSF trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas GNNSF's P/E ratio is -36.25. In terms of profitability, GNMSF's ROE is +0.14%, compared to GNNSF's ROE of -0.13%. Regarding short-term risk, GNMSF is more volatile compared to GNNSF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check GNNSF's competition here
GNMSF vs ASPHF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, ASPHF has a market cap of 3.2B. Regarding current trading prices, GNMSF is priced at $274.75, while ASPHF trades at $8.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas ASPHF's P/E ratio is -16.00. In terms of profitability, GNMSF's ROE is +0.14%, compared to ASPHF's ROE of -1.40%. Regarding short-term risk, GNMSF is more volatile compared to ASPHF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check ASPHF's competition here
GNMSF vs BRCTF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, BRCTF has a market cap of 2.9B. Regarding current trading prices, GNMSF is priced at $274.75, while BRCTF trades at $33.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas BRCTF's P/E ratio is 26.85. In terms of profitability, GNMSF's ROE is +0.14%, compared to BRCTF's ROE of +0.52%. Regarding short-term risk, GNMSF is less volatile compared to BRCTF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check BRCTF's competition here
GNMSF vs ZLDPF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, ZLDPF has a market cap of 2.9B. Regarding current trading prices, GNMSF is priced at $274.75, while ZLDPF trades at $40.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas ZLDPF's P/E ratio is 2.95. In terms of profitability, GNMSF's ROE is +0.14%, compared to ZLDPF's ROE of +0.48%. Regarding short-term risk, GNMSF is more volatile compared to ZLDPF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check ZLDPF's competition here
GNMSF vs TLPPF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, TLPPF has a market cap of 2.9B. Regarding current trading prices, GNMSF is priced at $274.75, while TLPPF trades at $8.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas TLPPF's P/E ratio is -423.75. In terms of profitability, GNMSF's ROE is +0.14%, compared to TLPPF's ROE of -0.02%. Regarding short-term risk, GNMSF is more volatile compared to TLPPF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check TLPPF's competition here
GNMSF vs MPSYF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, MPSYF has a market cap of 2.8B. Regarding current trading prices, GNMSF is priced at $274.75, while MPSYF trades at $73.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas MPSYF's P/E ratio is -12.13. In terms of profitability, GNMSF's ROE is +0.14%, compared to MPSYF's ROE of -1.84%. Regarding short-term risk, GNMSF is more volatile compared to MPSYF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check MPSYF's competition here
GNMSF vs GENSF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, GENSF has a market cap of 2.4B. Regarding current trading prices, GNMSF is priced at $274.75, while GENSF trades at $35.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas GENSF's P/E ratio is 37.86. In terms of profitability, GNMSF's ROE is +0.14%, compared to GENSF's ROE of +0.10%. Regarding short-term risk, GNMSF is more volatile compared to GENSF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check GENSF's competition here
GNMSF vs INCPF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, INCPF has a market cap of 2.3B. Regarding current trading prices, GNMSF is priced at $274.75, while INCPF trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas INCPF's P/E ratio is -77.50. In terms of profitability, GNMSF's ROE is +0.14%, compared to INCPF's ROE of -0.03%. Regarding short-term risk, GNMSF is less volatile compared to INCPF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check INCPF's competition here
GNMSF vs BVNRY Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, BVNRY has a market cap of 2.2B. Regarding current trading prices, GNMSF is priced at $274.75, while BVNRY trades at $9.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas BVNRY's P/E ratio is 5.97. In terms of profitability, GNMSF's ROE is +0.14%, compared to BVNRY's ROE of +0.11%. Regarding short-term risk, GNMSF is more volatile compared to BVNRY. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check BVNRY's competition here
GNMSF vs BVNKF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, BVNKF has a market cap of 2.2B. Regarding current trading prices, GNMSF is priced at $274.75, while BVNKF trades at $28.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas BVNKF's P/E ratio is 10.37. In terms of profitability, GNMSF's ROE is +0.14%, compared to BVNKF's ROE of +0.11%. Regarding short-term risk, GNMSF is more volatile compared to BVNKF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check BVNKF's competition here
GNMSF vs GLPGF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, GLPGF has a market cap of 2.2B. Regarding current trading prices, GNMSF is priced at $274.75, while GLPGF trades at $33.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas GLPGF's P/E ratio is -4.15. In terms of profitability, GNMSF's ROE is +0.14%, compared to GLPGF's ROE of +0.11%. Regarding short-term risk, GNMSF is more volatile compared to GLPGF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check GLPGF's competition here
GNMSF vs ASCLF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, ASCLF has a market cap of 2B. Regarding current trading prices, GNMSF is priced at $274.75, while ASCLF trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas ASCLF's P/E ratio is -47.50. In terms of profitability, GNMSF's ROE is +0.14%, compared to ASCLF's ROE of -0.13%. Regarding short-term risk, GNMSF is more volatile compared to ASCLF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check ASCLF's competition here
GNMSF vs MEOBF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, MEOBF has a market cap of 2B. Regarding current trading prices, GNMSF is priced at $274.75, while MEOBF trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas MEOBF's P/E ratio is -15.50. In terms of profitability, GNMSF's ROE is +0.14%, compared to MEOBF's ROE of -0.18%. Regarding short-term risk, GNMSF is less volatile compared to MEOBF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check MEOBF's competition here
GNMSF vs BIESF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, BIESF has a market cap of 1.6B. Regarding current trading prices, GNMSF is priced at $274.75, while BIESF trades at $32.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas BIESF's P/E ratio is -44.44. In terms of profitability, GNMSF's ROE is +0.14%, compared to BIESF's ROE of -0.07%. Regarding short-term risk, GNMSF is more volatile compared to BIESF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check BIESF's competition here
GNMSF vs PHMMF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, PHMMF has a market cap of 1.6B. Regarding current trading prices, GNMSF is priced at $274.75, while PHMMF trades at $92.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas PHMMF's P/E ratio is 40.08. In terms of profitability, GNMSF's ROE is +0.14%, compared to PHMMF's ROE of +0.35%. Regarding short-term risk, GNMSF is more volatile compared to PHMMF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check PHMMF's competition here
GNMSF vs ONTTF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, ONTTF has a market cap of 1.6B. Regarding current trading prices, GNMSF is priced at $274.75, while ONTTF trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas ONTTF's P/E ratio is -8.05. In terms of profitability, GNMSF's ROE is +0.14%, compared to ONTTF's ROE of -0.29%. Regarding short-term risk, GNMSF is less volatile compared to ONTTF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check ONTTF's competition here
GNMSF vs HBMHF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, HBMHF has a market cap of 1.3B. Regarding current trading prices, GNMSF is priced at $274.75, while HBMHF trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas HBMHF's P/E ratio is 17.33. In terms of profitability, GNMSF's ROE is +0.14%, compared to HBMHF's ROE of +0.36%. Regarding short-term risk, GNMSF is less volatile compared to HBMHF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check HBMHF's competition here
GNMSF vs SNBIF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, SNBIF has a market cap of 1.3B. Regarding current trading prices, GNMSF is priced at $274.75, while SNBIF trades at $16.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas SNBIF's P/E ratio is -49.85. In terms of profitability, GNMSF's ROE is +0.14%, compared to SNBIF's ROE of -0.89%. Regarding short-term risk, GNMSF is less volatile compared to SNBIF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check SNBIF's competition here
GNMSF vs CSPHF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, CSPHF has a market cap of 1.3B. Regarding current trading prices, GNMSF is priced at $274.75, while CSPHF trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas CSPHF's P/E ratio is -21.52. In terms of profitability, GNMSF's ROE is +0.14%, compared to CSPHF's ROE of -0.71%. Regarding short-term risk, GNMSF is more volatile compared to CSPHF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check CSPHF's competition here
GNMSF vs MDCLF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, MDCLF has a market cap of 1.2B. Regarding current trading prices, GNMSF is priced at $274.75, while MDCLF trades at $34.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas MDCLF's P/E ratio is -47.76. In terms of profitability, GNMSF's ROE is +0.14%, compared to MDCLF's ROE of +0.84%. Regarding short-term risk, GNMSF is more volatile compared to MDCLF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check MDCLF's competition here
GNMSF vs CSBTF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, CSBTF has a market cap of 1.2B. Regarding current trading prices, GNMSF is priced at $274.75, while CSBTF trades at $29.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas CSBTF's P/E ratio is -184.31. In terms of profitability, GNMSF's ROE is +0.14%, compared to CSBTF's ROE of +0.02%. Regarding short-term risk, GNMSF is more volatile compared to CSBTF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check CSBTF's competition here
GNMSF vs PHGUF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, PHGUF has a market cap of 1.1B. Regarding current trading prices, GNMSF is priced at $274.75, while PHGUF trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas PHGUF's P/E ratio is -151.00. In terms of profitability, GNMSF's ROE is +0.14%, compared to PHGUF's ROE of +0.01%. Regarding short-term risk, GNMSF is less volatile compared to PHGUF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check PHGUF's competition here
GNMSF vs NURPF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, NURPF has a market cap of 1B. Regarding current trading prices, GNMSF is priced at $274.75, while NURPF trades at $8.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas NURPF's P/E ratio is 51.38. In terms of profitability, GNMSF's ROE is +0.14%, compared to NURPF's ROE of +0.09%. Regarding short-term risk, GNMSF is more volatile compared to NURPF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check NURPF's competition here
GNMSF vs IDRSF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, IDRSF has a market cap of 1B. Regarding current trading prices, GNMSF is priced at $274.75, while IDRSF trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas IDRSF's P/E ratio is -6.11. In terms of profitability, GNMSF's ROE is +0.14%, compared to IDRSF's ROE of +0.10%. Regarding short-term risk, GNMSF is less volatile compared to IDRSF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check IDRSF's competition here
GNMSF vs PPTDF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, PPTDF has a market cap of 1B. Regarding current trading prices, GNMSF is priced at $274.75, while PPTDF trades at $7.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas PPTDF's P/E ratio is -43.06. In terms of profitability, GNMSF's ROE is +0.14%, compared to PPTDF's ROE of -0.03%. Regarding short-term risk, GNMSF is more volatile compared to PPTDF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check PPTDF's competition here
GNMSF vs BTTAY Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, BTTAY has a market cap of 943M. Regarding current trading prices, GNMSF is priced at $274.75, while BTTAY trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas BTTAY's P/E ratio is -67.31. In terms of profitability, GNMSF's ROE is +0.14%, compared to BTTAY's ROE of -0.07%. Regarding short-term risk, GNMSF is more volatile compared to BTTAY. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check BTTAY's competition here
GNMSF vs TKBIF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, TKBIF has a market cap of 879M. Regarding current trading prices, GNMSF is priced at $274.75, while TKBIF trades at $7.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas TKBIF's P/E ratio is -22.12. In terms of profitability, GNMSF's ROE is +0.14%, compared to TKBIF's ROE of N/A. Regarding short-term risk, GNMSF is less volatile compared to TKBIF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check TKBIF's competition here
GNMSF vs INRLF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, INRLF has a market cap of 877.7M. Regarding current trading prices, GNMSF is priced at $274.75, while INRLF trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas INRLF's P/E ratio is -6.80. In terms of profitability, GNMSF's ROE is +0.14%, compared to INRLF's ROE of -0.59%. Regarding short-term risk, GNMSF is less volatile compared to INRLF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check INRLF's competition here
GNMSF vs BPMUF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, BPMUF has a market cap of 871.3M. Regarding current trading prices, GNMSF is priced at $274.75, while BPMUF trades at $71.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas BPMUF's P/E ratio is 9.97. In terms of profitability, GNMSF's ROE is +0.14%, compared to BPMUF's ROE of +0.35%. Regarding short-term risk, GNMSF is more volatile compared to BPMUF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check BPMUF's competition here
GNMSF vs VBIZF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, VBIZF has a market cap of 724.5M. Regarding current trading prices, GNMSF is priced at $274.75, while VBIZF trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas VBIZF's P/E ratio is 34.34. In terms of profitability, GNMSF's ROE is +0.14%, compared to VBIZF's ROE of +0.04%. Regarding short-term risk, GNMSF is less volatile compared to VBIZF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check VBIZF's competition here
GNMSF vs IVEVF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, IVEVF has a market cap of 617.4M. Regarding current trading prices, GNMSF is priced at $274.75, while IVEVF trades at $4.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas IVEVF's P/E ratio is -1.00. In terms of profitability, GNMSF's ROE is +0.14%, compared to IVEVF's ROE of +5.38%. Regarding short-term risk, GNMSF is less volatile compared to IVEVF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check IVEVF's competition here
GNMSF vs CKDXF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, CKDXF has a market cap of 601.9M. Regarding current trading prices, GNMSF is priced at $274.75, while CKDXF trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas CKDXF's P/E ratio is -1.26. In terms of profitability, GNMSF's ROE is +0.14%, compared to CKDXF's ROE of +0.84%. Regarding short-term risk, GNMSF is more volatile compared to CKDXF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check CKDXF's competition here
GNMSF vs GNFTF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, GNFTF has a market cap of 544.4M. Regarding current trading prices, GNMSF is priced at $274.75, while GNFTF trades at $10.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas GNFTF's P/E ratio is -12.22. In terms of profitability, GNMSF's ROE is +0.14%, compared to GNFTF's ROE of -0.64%. Regarding short-term risk, GNMSF is more volatile compared to GNFTF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check GNFTF's competition here
GNMSF vs SOLTF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, SOLTF has a market cap of 492.3M. Regarding current trading prices, GNMSF is priced at $274.75, while SOLTF trades at $5.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas SOLTF's P/E ratio is -6.25. In terms of profitability, GNMSF's ROE is +0.14%, compared to SOLTF's ROE of -0.19%. Regarding short-term risk, GNMSF is more volatile compared to SOLTF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check SOLTF's competition here
GNMSF vs RAONF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, RAONF has a market cap of 451.7M. Regarding current trading prices, GNMSF is priced at $274.75, while RAONF trades at $2.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas RAONF's P/E ratio is -43.33. In terms of profitability, GNMSF's ROE is +0.14%, compared to RAONF's ROE of -0.26%. Regarding short-term risk, GNMSF is less volatile compared to RAONF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check RAONF's competition here
GNMSF vs GNFTY Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, GNFTY has a market cap of 447.8M. Regarding current trading prices, GNMSF is priced at $274.75, while GNFTY trades at $8.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas GNFTY's P/E ratio is -9.94. In terms of profitability, GNMSF's ROE is +0.14%, compared to GNFTY's ROE of -0.69%. Regarding short-term risk, GNMSF is more volatile compared to GNFTY. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check GNFTY's competition here
GNMSF vs TBGNF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, TBGNF has a market cap of 433.7M. Regarding current trading prices, GNMSF is priced at $274.75, while TBGNF trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas TBGNF's P/E ratio is -0.25. In terms of profitability, GNMSF's ROE is +0.14%, compared to TBGNF's ROE of -0.01%. Regarding short-term risk, GNMSF is more volatile compared to TBGNF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check TBGNF's competition here
GNMSF vs CLVLF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, CLVLF has a market cap of 424.1M. Regarding current trading prices, GNMSF is priced at $274.75, while CLVLF trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas CLVLF's P/E ratio is 16.90. In terms of profitability, GNMSF's ROE is +0.14%, compared to CLVLF's ROE of +0.13%. Regarding short-term risk, GNMSF is more volatile compared to CLVLF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check CLVLF's competition here
GNMSF vs PTCHF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, PTCHF has a market cap of 374.8M. Regarding current trading prices, GNMSF is priced at $274.75, while PTCHF trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas PTCHF's P/E ratio is 9.12. In terms of profitability, GNMSF's ROE is +0.14%, compared to PTCHF's ROE of +0.13%. Regarding short-term risk, GNMSF is more volatile compared to PTCHF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check PTCHF's competition here
GNMSF vs AVCTF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, AVCTF has a market cap of 363.7M. Regarding current trading prices, GNMSF is priced at $274.75, while AVCTF trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas AVCTF's P/E ratio is -5.54. In terms of profitability, GNMSF's ROE is +0.14%, compared to AVCTF's ROE of -3.76%. Regarding short-term risk, GNMSF is more volatile compared to AVCTF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check AVCTF's competition here
GNMSF vs CYDY Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, CYDY has a market cap of 350.6M. Regarding current trading prices, GNMSF is priced at $274.75, while CYDY trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas CYDY's P/E ratio is -9.20. In terms of profitability, GNMSF's ROE is +0.14%, compared to CYDY's ROE of +0.38%. Regarding short-term risk, GNMSF is less volatile compared to CYDY. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check CYDY's competition here
GNMSF vs CLVLY Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, CLVLY has a market cap of 340.6M. Regarding current trading prices, GNMSF is priced at $274.75, while CLVLY trades at $6.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas CLVLY's P/E ratio is 15.08. In terms of profitability, GNMSF's ROE is +0.14%, compared to CLVLY's ROE of +0.13%. Regarding short-term risk, GNMSF is more volatile compared to CLVLY. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check CLVLY's competition here
GNMSF vs NWBO Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, NWBO has a market cap of 338.7M. Regarding current trading prices, GNMSF is priced at $274.75, while NWBO trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas NWBO's P/E ratio is -3.66. In terms of profitability, GNMSF's ROE is +0.14%, compared to NWBO's ROE of +0.92%. Regarding short-term risk, GNMSF is less volatile compared to NWBO. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check NWBO's competition here
GNMSF vs CMVLF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, CMVLF has a market cap of 325.5M. Regarding current trading prices, GNMSF is priced at $274.75, while CMVLF trades at $4.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas CMVLF's P/E ratio is -13.64. In terms of profitability, GNMSF's ROE is +0.14%, compared to CMVLF's ROE of -0.32%. Regarding short-term risk, GNMSF is more volatile compared to CMVLF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check CMVLF's competition here
GNMSF vs HLOSF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, HLOSF has a market cap of 318.2M. Regarding current trading prices, GNMSF is priced at $274.75, while HLOSF trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas HLOSF's P/E ratio is -16.18. In terms of profitability, GNMSF's ROE is +0.14%, compared to HLOSF's ROE of -0.80%. Regarding short-term risk, GNMSF is less volatile compared to HLOSF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check HLOSF's competition here
GNMSF vs NGENF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, NGENF has a market cap of 312.9M. Regarding current trading prices, GNMSF is priced at $274.75, while NGENF trades at $3.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas NGENF's P/E ratio is -15.19. In terms of profitability, GNMSF's ROE is +0.14%, compared to NGENF's ROE of -974.60%. Regarding short-term risk, GNMSF is more volatile compared to NGENF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check NGENF's competition here
GNMSF vs FGHQF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, FGHQF has a market cap of 304.2M. Regarding current trading prices, GNMSF is priced at $274.75, while FGHQF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas FGHQF's P/E ratio is 15.00. In terms of profitability, GNMSF's ROE is +0.14%, compared to FGHQF's ROE of +0.01%. Regarding short-term risk, GNMSF is more volatile compared to FGHQF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check FGHQF's competition here
GNMSF vs PBBIF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, PBBIF has a market cap of 286.9M. Regarding current trading prices, GNMSF is priced at $274.75, while PBBIF trades at $24.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas PBBIF's P/E ratio is 266.67. In terms of profitability, GNMSF's ROE is +0.14%, compared to PBBIF's ROE of +0.01%. Regarding short-term risk, GNMSF is more volatile compared to PBBIF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check PBBIF's competition here
GNMSF vs SLNCF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, SLNCF has a market cap of 283.4M. Regarding current trading prices, GNMSF is priced at $274.75, while SLNCF trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas SLNCF's P/E ratio is -3.17. In terms of profitability, GNMSF's ROE is +0.14%, compared to SLNCF's ROE of -4.29%. Regarding short-term risk, GNMSF is more volatile compared to SLNCF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check SLNCF's competition here
GNMSF vs KNTPF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, KNTPF has a market cap of 265M. Regarding current trading prices, GNMSF is priced at $274.75, while KNTPF trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas KNTPF's P/E ratio is -11.30. In terms of profitability, GNMSF's ROE is +0.14%, compared to KNTPF's ROE of -0.35%. Regarding short-term risk, GNMSF is more volatile compared to KNTPF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check KNTPF's competition here
GNMSF vs ORYZF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, ORYZF has a market cap of 263.4M. Regarding current trading prices, GNMSF is priced at $274.75, while ORYZF trades at $3.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas ORYZF's P/E ratio is -83.50. In terms of profitability, GNMSF's ROE is +0.14%, compared to ORYZF's ROE of -0.03%. Regarding short-term risk, GNMSF is less volatile compared to ORYZF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check ORYZF's competition here
GNMSF vs ORPOF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, ORPOF has a market cap of 260.3M. Regarding current trading prices, GNMSF is priced at $274.75, while ORPOF trades at $11.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas ORPOF's P/E ratio is -11.86. In terms of profitability, GNMSF's ROE is +0.14%, compared to ORPOF's ROE of N/A. Regarding short-term risk, GNMSF is more volatile compared to ORPOF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check ORPOF's competition here
GNMSF vs SPHDF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, SPHDF has a market cap of 249.6M. Regarding current trading prices, GNMSF is priced at $274.75, while SPHDF trades at $17.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas SPHDF's P/E ratio is -2.62. In terms of profitability, GNMSF's ROE is +0.14%, compared to SPHDF's ROE of -5.22%. Regarding short-term risk, GNMSF is more volatile compared to SPHDF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check SPHDF's competition here
GNMSF vs HNSBF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, HNSBF has a market cap of 245.8M. Regarding current trading prices, GNMSF is priced at $274.75, while HNSBF trades at $2.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas HNSBF's P/E ratio is -4.14. In terms of profitability, GNMSF's ROE is +0.14%, compared to HNSBF's ROE of +1.24%. Regarding short-term risk, GNMSF is more volatile compared to HNSBF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check HNSBF's competition here
GNMSF vs NWPHF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, NWPHF has a market cap of 239.5M. Regarding current trading prices, GNMSF is priced at $274.75, while NWPHF trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas NWPHF's P/E ratio is N/A. In terms of profitability, GNMSF's ROE is +0.14%, compared to NWPHF's ROE of +16.69%. Regarding short-term risk, GNMSF is more volatile compared to NWPHF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check NWPHF's competition here
GNMSF vs CAIHF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, CAIHF has a market cap of 217.4M. Regarding current trading prices, GNMSF is priced at $274.75, while CAIHF trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas CAIHF's P/E ratio is 2.80. In terms of profitability, GNMSF's ROE is +0.14%, compared to CAIHF's ROE of +0.12%. Regarding short-term risk, GNMSF is less volatile compared to CAIHF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check CAIHF's competition here
GNMSF vs BOVNF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, BOVNF has a market cap of 216.4M. Regarding current trading prices, GNMSF is priced at $274.75, while BOVNF trades at $3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas BOVNF's P/E ratio is -7.00. In terms of profitability, GNMSF's ROE is +0.14%, compared to BOVNF's ROE of -0.47%. Regarding short-term risk, GNMSF is less volatile compared to BOVNF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check BOVNF's competition here
GNMSF vs FPHAF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, FPHAF has a market cap of 209.5M. Regarding current trading prices, GNMSF is priced at $274.75, while FPHAF trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas FPHAF's P/E ratio is -7.50. In terms of profitability, GNMSF's ROE is +0.14%, compared to FPHAF's ROE of +0.00%. Regarding short-term risk, GNMSF is more volatile compared to FPHAF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check FPHAF's competition here
GNMSF vs IPHYF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, IPHYF has a market cap of 186.5M. Regarding current trading prices, GNMSF is priced at $274.75, while IPHYF trades at $1.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas IPHYF's P/E ratio is -3.16. In terms of profitability, GNMSF's ROE is +0.14%, compared to IPHYF's ROE of -6.59%. Regarding short-term risk, GNMSF is more volatile compared to IPHYF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check IPHYF's competition here
GNMSF vs MLLCF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, MLLCF has a market cap of 185.5M. Regarding current trading prices, GNMSF is priced at $274.75, while MLLCF trades at $4.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas MLLCF's P/E ratio is -2.36. In terms of profitability, GNMSF's ROE is +0.14%, compared to MLLCF's ROE of -0.60%. Regarding short-term risk, GNMSF is less volatile compared to MLLCF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check MLLCF's competition here
GNMSF vs ADOCY Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, ADOCY has a market cap of 170.4M. Regarding current trading prices, GNMSF is priced at $274.75, while ADOCY trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas ADOCY's P/E ratio is -3.36. In terms of profitability, GNMSF's ROE is +0.14%, compared to ADOCY's ROE of +1.86%. Regarding short-term risk, GNMSF is more volatile compared to ADOCY. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check ADOCY's competition here
GNMSF vs SCNLF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, SCNLF has a market cap of 162.7M. Regarding current trading prices, GNMSF is priced at $274.75, while SCNLF trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas SCNLF's P/E ratio is -15.68. In terms of profitability, GNMSF's ROE is +0.14%, compared to SCNLF's ROE of +0.90%. Regarding short-term risk, GNMSF is more volatile compared to SCNLF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check SCNLF's competition here
GNMSF vs BBIXF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, BBIXF has a market cap of 157.7M. Regarding current trading prices, GNMSF is priced at $274.75, while BBIXF trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas BBIXF's P/E ratio is -13.50. In terms of profitability, GNMSF's ROE is +0.14%, compared to BBIXF's ROE of -8.24%. Regarding short-term risk, GNMSF is less volatile compared to BBIXF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check BBIXF's competition here
GNMSF vs AMGXF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, AMGXF has a market cap of 139.1M. Regarding current trading prices, GNMSF is priced at $274.75, while AMGXF trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas AMGXF's P/E ratio is -0.46. In terms of profitability, GNMSF's ROE is +0.14%, compared to AMGXF's ROE of -0.45%. Regarding short-term risk, GNMSF is less volatile compared to AMGXF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check AMGXF's competition here
GNMSF vs SPHRF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, SPHRF has a market cap of 138.6M. Regarding current trading prices, GNMSF is priced at $274.75, while SPHRF trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas SPHRF's P/E ratio is -33.00. In terms of profitability, GNMSF's ROE is +0.14%, compared to SPHRF's ROE of -0.16%. Regarding short-term risk, GNMSF is more volatile compared to SPHRF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check SPHRF's competition here
GNMSF vs SPHRY Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, SPHRY has a market cap of 138.6M. Regarding current trading prices, GNMSF is priced at $274.75, while SPHRY trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas SPHRY's P/E ratio is -55.00. In terms of profitability, GNMSF's ROE is +0.14%, compared to SPHRY's ROE of -0.05%. Regarding short-term risk, GNMSF is more volatile compared to SPHRY. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check SPHRY's competition here
GNMSF vs BRIBF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, BRIBF has a market cap of 135.7M. Regarding current trading prices, GNMSF is priced at $274.75, while BRIBF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas BRIBF's P/E ratio is -2.69. In terms of profitability, GNMSF's ROE is +0.14%, compared to BRIBF's ROE of -0.07%. Regarding short-term risk, GNMSF is less volatile compared to BRIBF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check BRIBF's competition here
GNMSF vs HBPCF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, HBPCF has a market cap of 132.1M. Regarding current trading prices, GNMSF is priced at $274.75, while HBPCF trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas HBPCF's P/E ratio is -34.60. In terms of profitability, GNMSF's ROE is +0.14%, compared to HBPCF's ROE of -0.37%. Regarding short-term risk, GNMSF is more volatile compared to HBPCF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check HBPCF's competition here
GNMSF vs TRGNF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, TRGNF has a market cap of 132.1M. Regarding current trading prices, GNMSF is priced at $274.75, while TRGNF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas TRGNF's P/E ratio is -3.03. In terms of profitability, GNMSF's ROE is +0.14%, compared to TRGNF's ROE of -6.34%. Regarding short-term risk, GNMSF is less volatile compared to TRGNF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check TRGNF's competition here
GNMSF vs NDTP Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, NDTP has a market cap of 130M. Regarding current trading prices, GNMSF is priced at $274.75, while NDTP trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas NDTP's P/E ratio is -2.32. In terms of profitability, GNMSF's ROE is +0.14%, compared to NDTP's ROE of -0.24%. Regarding short-term risk, GNMSF is less volatile compared to NDTP. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check NDTP's competition here
GNMSF vs JWCTF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, JWCTF has a market cap of 127.5M. Regarding current trading prices, GNMSF is priced at $274.75, while JWCTF trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas JWCTF's P/E ratio is -1.40. In terms of profitability, GNMSF's ROE is +0.14%, compared to JWCTF's ROE of -0.59%. Regarding short-term risk, GNMSF is less volatile compared to JWCTF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check JWCTF's competition here
GNMSF vs AAPGV Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, AAPGV has a market cap of 127.3M. Regarding current trading prices, GNMSF is priced at $274.75, while AAPGV trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas AAPGV's P/E ratio is N/A. In terms of profitability, GNMSF's ROE is +0.14%, compared to AAPGV's ROE of -2.49%. Regarding short-term risk, GNMSF is less volatile compared to AAPGV. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check AAPGV's competition here
GNMSF vs PSTTF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, PSTTF has a market cap of 117.5M. Regarding current trading prices, GNMSF is priced at $274.75, while PSTTF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas PSTTF's P/E ratio is -29.00. In terms of profitability, GNMSF's ROE is +0.14%, compared to PSTTF's ROE of N/A. Regarding short-term risk, GNMSF is more volatile compared to PSTTF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check PSTTF's competition here
GNMSF vs MSCLF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, MSCLF has a market cap of 113M. Regarding current trading prices, GNMSF is priced at $274.75, while MSCLF trades at $7.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas MSCLF's P/E ratio is 2.84. In terms of profitability, GNMSF's ROE is +0.14%, compared to MSCLF's ROE of -0.52%. Regarding short-term risk, GNMSF is more volatile compared to MSCLF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check MSCLF's competition here
GNMSF vs ATGGF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, ATGGF has a market cap of 111.2M. Regarding current trading prices, GNMSF is priced at $274.75, while ATGGF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas ATGGF's P/E ratio is N/A. In terms of profitability, GNMSF's ROE is +0.14%, compared to ATGGF's ROE of -1.34%. Regarding short-term risk, GNMSF is less volatile compared to ATGGF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check ATGGF's competition here
GNMSF vs EPRXF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, EPRXF has a market cap of 108.3M. Regarding current trading prices, GNMSF is priced at $274.75, while EPRXF trades at $3.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas EPRXF's P/E ratio is -2.69. In terms of profitability, GNMSF's ROE is +0.14%, compared to EPRXF's ROE of -4.83%. Regarding short-term risk, GNMSF is less volatile compared to EPRXF. This indicates potentially lower risk in terms of short-term price fluctuations for GNMSF.Check EPRXF's competition here
GNMSF vs ADOIF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, ADOIF has a market cap of 103.7M. Regarding current trading prices, GNMSF is priced at $274.75, while ADOIF trades at $8.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas ADOIF's P/E ratio is -2.59. In terms of profitability, GNMSF's ROE is +0.14%, compared to ADOIF's ROE of +6.08%. Regarding short-term risk, GNMSF is more volatile compared to ADOIF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check ADOIF's competition here
GNMSF vs BXPHF Comparison March 2026
GNMSF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GNMSF stands at 16.9B. In comparison, BXPHF has a market cap of 94.9M. Regarding current trading prices, GNMSF is priced at $274.75, while BXPHF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GNMSF currently has a P/E ratio of 17.89, whereas BXPHF's P/E ratio is -1.43. In terms of profitability, GNMSF's ROE is +0.14%, compared to BXPHF's ROE of -1.31%. Regarding short-term risk, GNMSF is more volatile compared to BXPHF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMSF.Check BXPHF's competition here